SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-250341
Filing Date
2023-10-04
Accepted
2023-10-04 07:00:30
Documents
12
Period of Report
2023-10-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d547449d8k.htm   iXBRL 8-K 22850
  Complete submission text file 0001193125-23-250341.txt   140092

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20231002.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20231002_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20231002_pre.xml EX-101.PRE 10824
6 EXTRACTED XBRL INSTANCE DOCUMENT d547449d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 231306559
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences